Department of Oncology, The First Affiliated Hospital, Zhengzhou University, Zhengzhou, China.
Department of Pathology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Front Immunol. 2022 May 17;13:899073. doi: 10.3389/fimmu.2022.899073. eCollection 2022.
Castleman disease (CD) is a rare lymphoproliferative disorder. The mechanistic target of rapamycin (mTOR) pathway is a key regulator of various cellular functions, which may be related with the potential mechanisms of CD occurrence. We retrospectively collected the clinical information of 60 CD patients diagnosed in the First Affiliated Hospital of Zhengzhou University. And FFPE biopsy specimens were collected from 31 patients (12 unicentric CD patients and 19 multicentric CD patients) to detect the mTOR pathway protein expression. We are the first to demonstrate that thrombocytopenia and hypoalbuminemia are independent poor prognostic factors for CD. Moreover, mTOR activation was higher in CD compared to reactive lymphoid hyperplasia (used as a control group). This study offers some elucidation for the management and treatment of CD patients.
血管滤泡性淋巴结增生症(CD)是一种罕见的淋巴组织增生性疾病。雷帕霉素靶蛋白(mTOR)通路是各种细胞功能的关键调节剂,可能与 CD 发生的潜在机制有关。我们回顾性收集了在郑州大学第一附属医院诊断的 60 例 CD 患者的临床资料。并收集了 31 例患者(12 例单中心 CD 患者和 19 例多中心 CD 患者)的 FFPE 活检标本,以检测 mTOR 通路蛋白表达。我们首次证明血小板减少和低白蛋白血症是 CD 的独立不良预后因素。此外,与反应性淋巴组织增生(用作对照组)相比,CD 中的 mTOR 激活更高。这项研究为 CD 患者的管理和治疗提供了一些依据。